

Applicants : Maureen J. Charron and Ellen B. Katz
Serial No. : 09/886,954
Filed : June 21, 2001
Page 2

- II. Claims 1-3, 4-7, 11-13, 14-17 and 21-23 , drawn to a method of diagnosis, assessing the efficacy of therapy and prognosis of a subject who has defect in cell proliferation by assaying GLUTx expression using a antibody;
- III. Claims 24-28, drawn to a method of treating a defect in cell proliferation in a subject using a compound that inhibits GLUTx;
- IV. Claims 24-27 and 29, drawn to a method of treating a defect in cell proliferation in a subject using an oligonucleotide antisense to GLUTx;
- V. Claims 30-31 and 34, drawn to method of treating ischemia in a subject by administering GLUTx protein;
- VI. Claims 32-34, drawn to method of treating ischemia in a subject by administering nucleic acid encoding GLUTx; and
- VII. Claim 35, drawn to method of treating ischemia in a subject by administering a GLUTx modulator.

In response to the restriction requirement, applicants hereby elect, with traverse, to prosecute the invention identified by the Examiner as Group II, i.e. Claims 1-3, 4-7, 11-13, 14-17 and 21-23, drawn to a method of diagnosis, assessing the efficacy of therapy and prognosis of a subject who has defect in cell proliferation by assaying GLUTx expression using a antibody.

Applicants request that the Examiner reconsider and rejoin Groups I and II. Applicants note that Groups I and II are drawn to methods of diagnosis, and assessing